2022年度前列腺癌基础研究及临床诊疗新进展

Advances in basic research,clinical diagnosis and treatment of prostate cancer in 2022

中国初诊的前列腺癌患者中40%~70%已处于转移性疾病阶段,而前列腺癌发生、发展的时空异质性及独特的转移模式使得基于活检组织取材分析免疫标志物的方式困难重重。大量基础与临床研究的推进,使得前列腺癌在发病机制、诊断方法、围手术期处理、放疗技术和晚期疾病的系统治疗等方面取得了新进展。这些成果不断丰富前列腺癌患者的诊治手段,改善其预后。现对2022年度前列腺癌研究领域的重大进展进行综述。

About 40%-70%of newly diagnosed prostate cancer patients in China are in the stage of metastatic disease,and the spatio-temporal heterogeneity of the occurrence and development of prostate cancer and the unique metastasis pattern make it difficult to analyze immune markers based on biopsy tissue.With the advancement of many basic and clinical studies,new advances have been made in the pathogenesis,diagnostic methods,perioperative management,radiotherapy techniques and systematic treatment of advanced diseases of prostate cancer.These results continuously enrich the means of diagnosis and treatment of prostate cancer patients and improve their prognosis.Here was a review of the major advances in prostate cancer research in 2022.